Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by bligickaon Jan 27, 2021 6:19pm
78 Views
Post# 32403421

No phase 1 yet !!!

No phase 1 yet !!!Goren has delayed us so long ....how can they ever produce a appoved  vaccine ...they haven't even proven it works ........

So not all the mice produced a immune response...... after a month ???

“ The study is proceeding as planned. Mice were successfully vaccinated, and we have detected an antigen-specific T cell response in several of the animals receiving the vaccine candidate. We are pleased with the progress of this study and look forward to updating our shareholders and the scientific community with the results once we complete the experiment,” said David Goren, Vaxil’s Chairman and Chief Executive Officer .


<< Previous
Bullboard Posts
Next >>